FY2024 EPS Estimates for Immunocore Boosted by HC Wainwright

Immunocore Holdings plc (NASDAQ:IMCR - Free Report) - Equities research analysts at HC Wainwright lifted their FY2024 EPS estimates for shares of Immunocore in a research note issued on Thursday, November 7th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($1.33) per share for the year, up from their previous estimate of ($2.14). HC Wainwright currently has a "Buy" rating and a $100.00 target price on the stock. The consensus estimate for Immunocore's current full-year earnings is ($1.11) per share. HC Wainwright also issued estimates for Immunocore's Q4 2024 earnings at ($0.78) EPS, Q1 2025 earnings at ($0.42) EPS, Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.96) EPS, FY2025 earnings at ($2.41) EPS, FY2026 earnings at ($2.34) EPS, FY2027 earnings at $1.04 EPS and FY2028 earnings at $4.21 EPS.

Other equities research analysts have also issued research reports about the stock. Barclays decreased their price objective on shares of Immunocore from $92.00 to $66.00 and set an "overweight" rating on the stock in a report on Friday, August 9th. Needham & Company LLC cut their target price on shares of Immunocore from $78.00 to $71.00 and set a "buy" rating on the stock in a research report on Thursday. Guggenheim downgraded shares of Immunocore from a "buy" rating to a "neutral" rating in a research report on Monday, October 7th. Oppenheimer restated an "outperform" rating and set a $89.00 target price (up from $87.00) on shares of Immunocore in a research report on Friday, August 9th. Finally, Mizuho downgraded shares of Immunocore from an "outperform" rating to a "neutral" rating and cut their target price for the company from $72.00 to $38.00 in a research report on Monday. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $69.18.

Immunocore Price Performance

NASDAQ:IMCR traded down $0.05 during mid-day trading on Monday, reaching $34.64. 224,802 shares of the company were exchanged, compared to its average volume of 524,539. Immunocore has a 12 month low of $29.72 and a 12 month high of $76.98. The company has a fifty day moving average of $32.64 and a 200 day moving average of $39.26. The company has a quick ratio of 5.15, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. The stock has a market cap of $1.73 billion, a PE ratio of -36.52 and a beta of 0.72.

Immunocore (NASDAQ:IMCR - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.17 EPS for the quarter, topping analysts' consensus estimates of ($0.33) by $0.50. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The firm had revenue of $80.25 million for the quarter, compared to analyst estimates of $78.94 million. During the same quarter in the prior year, the firm earned ($0.59) EPS. The company's revenue was up 23.7% on a year-over-year basis.

Institutional Trading of Immunocore

Hedge funds have recently modified their holdings of the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in Immunocore by 86.3% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 342,000 shares of the company's stock worth $22,230,000 after buying an additional 158,455 shares during the period. Orion Portfolio Solutions LLC raised its holdings in Immunocore by 33.7% during the 1st quarter. Orion Portfolio Solutions LLC now owns 23,127 shares of the company's stock worth $1,503,000 after buying an additional 5,826 shares during the period. Nan Fung Group Holdings Ltd acquired a new stake in Immunocore during the 1st quarter worth approximately $439,000. Janus Henderson Group PLC grew its stake in shares of Immunocore by 45.8% during the 1st quarter. Janus Henderson Group PLC now owns 257,080 shares of the company's stock worth $16,711,000 after acquiring an additional 80,748 shares in the last quarter. Finally, Tidal Investments LLC bought a new position in shares of Immunocore during the 1st quarter worth approximately $423,000. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.